Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.
Document Type
Journal Article
Publication Date
1-2016
Journal
The Lancet Infectious Diseases
Volume
16
Issue
1
Inclusive Pages
43-52
DOI
10.1016/S1473-3099(15)00348-5
APA Citation
Anthony Mills, MD, Jose R Arribas, MD, Prof Jaime Andrade-Villanueva, MD, Giovanni DiPerri, MD, Prof Jan Van Lunzen, MD, Ellen Koenig, MD, Richard Elion, MD. (2015) Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. The Lancet: Infectious Diseases, 16(1), 43-52. doi: 10.1016/S1473-3099(15)00348-5
Peer Reviewed
1
